García-Pérez LE - Search Results

1

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.

Boye KS, Sapin H, García-Pérez LE, Rosilio M, Orsini Federici M, Heitmann E, Jung H, Aigner U, Guerci B, Giorgino F, Norrbacka K. Boye KS, et al. Among authors: garcia perez le. Diabetes Ther. 2020 Oct;11(10):2383-2399. doi: 10.1007/s13300-020-00908-9. Epub 2020 Sep 3. Diabetes Ther. 2020. PMID: 32880876 Free PMC article.

2

Adherence to therapies in patients with type 2 diabetes.

García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. García-Pérez LE, et al. Diabetes Ther. 2013 Dec;4(2):175-94. doi: 10.1007/s13300-013-0034-y. Epub 2013 Aug 30. Diabetes Ther. 2013. PMID: 23990497 Free PMC article.

3

Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.

Anderson JE, Thieu VT, Boye KS, Hietpas RT, Garcia-Perez LE. Anderson JE, et al. Postgrad Med. 2016 Nov;128(8):810-821. doi: 10.1080/00325481.2016.1218260. Epub 2016 Aug 12. Postgrad Med. 2016. PMID: 27488824 Review.

4

Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database.

Boye KS, Curtis SE, Lage MJ, Garcia-Perez LE. Boye KS, et al. Patient Prefer Adherence. 2016 Aug 16;10:1573-81. doi: 10.2147/PPA.S107543. eCollection 2016. Patient Prefer Adherence. 2016. PMID: 27574406 Free PMC article.

5

Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.

Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N, Giorgino F. Gallwitz B, et al. Diabetes Obes Metab. 2018 Feb;20(2):409-418. doi: 10.1111/dom.13086. Epub 2017 Oct 5. Diabetes Obes Metab. 2018. PMID: 28817231 Free PMC article. Clinical Trial.

6

Medication adherence and improved outcomes among patients with type 2 diabetes.

Curtis SE, Boye KS, Lage MJ, Garcia-Perez LE. Curtis SE, et al. Am J Manag Care. 2017 Jul 1;23(7):e208-e214. Am J Manag Care. 2017. PMID: 28850793 Free article.

7

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC. Boye KS, et al. Diabetes Obes Metab. 2019 Jun;21(6):1299-1304. doi: 10.1111/dom.13649. Epub 2019 Mar 12. Diabetes Obes Metab. 2019. PMID: 30714309 Free PMC article.

8

Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.

Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE. Thieu VT, et al. Patient Prefer Adherence. 2019 Apr 17;13:561-576. doi: 10.2147/PPA.S187907. eCollection 2019. Patient Prefer Adherence. 2019. PMID: 31114170 Free PMC article. Review.

9

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.

Boye KS, Stein D, Matza LS, Jordan J, Yu R, Norrbacka K, Hassan SW, García-Pérez LE. Boye KS, et al. Drugs R D. 2019 Jun;19(2):213-225. doi: 10.1007/s40268-019-0273-0. Drugs R D. 2019. PMID: 31115873 Free PMC article.

10

Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.

Giorgino F, Yu M, Haupt A, Milicevic Z, García-Pérez LE. Giorgino F, et al. Diabetes Obes Metab. 2019 Nov;21(11):2570-2575. doi: 10.1111/dom.13844. Epub 2019 Aug 16. Diabetes Obes Metab. 2019. PMID: 31364266 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page